NR4A1 and cancer: To assess the general applicability of the methodology also to other cancer cells beyond the PC‐3 prostate cell line, we conducted similar metabotyping experiments with two additional cell lines: MCF‐7 hormone receptor‐positive breast cancer cells and MHH‐ES‐1 Ewing's sarcoma cells.